Intech Investment Management LLC Buys Shares of 28,228 Vaxcyte, Inc. (NASDAQ:PCVX)

Intech Investment Management LLC bought a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the 3rd quarter, Holdings Channel reports. The fund bought 28,228 shares of the company’s stock, valued at approximately $3,226,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Blue Trust Inc. lifted its stake in shares of Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares during the period. Nisa Investment Advisors LLC increased its holdings in Vaxcyte by 5.2% in the third quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company’s stock valued at $252,000 after buying an additional 110 shares in the last quarter. CIBC Asset Management Inc lifted its position in shares of Vaxcyte by 3.6% during the 3rd quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock valued at $358,000 after acquiring an additional 110 shares during the period. Amalgamated Bank boosted its stake in shares of Vaxcyte by 4.2% during the 2nd quarter. Amalgamated Bank now owns 3,759 shares of the company’s stock worth $284,000 after acquiring an additional 150 shares in the last quarter. Finally, Riverview Trust Co purchased a new stake in shares of Vaxcyte during the 3rd quarter worth approximately $27,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Trading Up 0.2 %

Vaxcyte stock opened at $88.54 on Friday. The stock has a market cap of $11.04 billion, a PE ratio of -19.25 and a beta of 1.01. The stock has a 50-day moving average price of $107.89 and a 200 day moving average price of $89.41. Vaxcyte, Inc. has a 52 week low of $48.24 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter last year, the business posted ($0.91) earnings per share. On average, equities analysts predict that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on PCVX shares. BTIG Research raised their price objective on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. Jefferies Financial Group increased their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Leerink Partners lifted their target price on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. Finally, Mizuho upped their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $147.50.

Insiders Place Their Bets

In related news, SVP Elvia Cowan sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total value of $538,350.00. Following the completion of the transaction, the senior vice president now directly owns 12,723 shares in the company, valued at approximately $1,369,885.41. This represents a 28.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Andrew Guggenhime sold 42,000 shares of the firm’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00. Following the completion of the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,429,294.37. The trade was a 31.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 102,464 shares of company stock valued at $11,455,576 in the last quarter. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.